投资观察08-01
制药公司礼来股价盘前上涨2%，至755美元。据华盛顿邮报报道，Trump政府正计划在Medicare和Medicaid下覆盖减肥药物。
报道称，拟议计划将允许州Medicaid项目和Medicare Part D保险计划自愿覆盖GLP-1药物，如Novo Nordisk的Ozempic和Wegovy，以及礼来的Mounjaro和Zepbound等用于体重管理的药物。
据华盛顿邮报援引相关文件报道，拟议计划预计将于2026年4月对Medicaid开始实施，2027年1月对Medicare计划开始实施。
Medicare与Medicaid服务中心、Eli Lilly和Novo Nordisk均未立即回应路透社的置评请求。
截至上一交易日收盘，礼来年初至今下跌4.1%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
